Roche Sequencing Solutions, Inc.

Revolution Medicines, Inc.

Genia Technologies, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Christos Tzitzilonis

Liv Elisabeth Jensen

Cynthia Ann Cech

Elena S Koltun

Adrian L Gill

Naing N Aay

Andreas Buckl

Kevin T Mellem

Corissa Harris

Matthew Dipietro

Walter S Won

Dhruti Vasudev Dalal

Charlotte Yang

Tim Craig

Jie Jack Li

Alexander Yang

Michael Dorwart

Timothy Kellogg Craig

Marshall Winston Porter

Jennifer Pitzen

Gang Wang

Brian R Blank

Alexander Hyun-min Yang

Dmitriy Gremyachinskiy

James Joseph Cregg

Christopher Michael Semko

Gert Kiss

Ashutosh S Jogalekar

Ash Jogalekar

Cynthia Cech

Adrian Liam Gill

Dhruti Dalal

Liv Jensen

Alexander Hyun-Min Yang

Liv Elizabeth Jensen

Timothy Kellog Cech

The present disclosure provides variant OmpG polypeptides, compositions comprising the OmpG variant polypeptides, and methods for using the variant OmpG polypeptides as nanopores for determining the sequence of single stranded nucleic acids. The variant OmpG nanopores reduce the ionic current noise versus the parental OmpG polypeptide from which they are derived and thereby enable sequencing of polynucleotides with single nucleotide resolution. The reduced ionic current noise also provides for the use of these OmpG nanopore variants in other single molecule sensing applications, e.g., protein sequencing.

OmpG variants

The present disclosure is directed to inhibitors of SHP2 having the formula:

Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors

OMPG variants

The present disclosure relates to relates methods and associated compositions that provide fast, efficient site-selective conjugation of a protein, such as the pore-forming protein α-hemolysin, to a biomolecule, such as a DNA polymerase, and the use of such site-selective protein-biomolecule conjugates in nanopore devices and methods.

Site-specific bio-conjugation methods and compositions useful for nanopore systems

The present disclosure is directed to compounds of Formula IV: as inhibitors of SHP2 and their use in the treatment of diseases associated with SHP2. Also disclosed are pharmaceutical compositions comprising the same.

The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors

Polycyclic compounds as allosteric SHP2 inhibitors

Described herein are engineered alpha-hemolysin subunits having mutated oligomerization domains for assembling into heptameric nanopores in lipid bilayers.

Alpha-hemolysin variants

The present disclosure relates to relates methods and associated compositions that provide fast, efficient site-selective conjugation of a protein, such as the pore-forming protein &#x3b1;-hemolysin, to a biomolecule, such as a DNA polymerase, and the use of such site-selective protein-biomolecule conjugates in nanopore devices and methods.

Growing community of inventors

Mountain View, CA, United States of America

Christos Tzitzilonis